Thirty-six adults with chronic myelogenous leukemia (CML) in second or greater chronic phase, accelerated phase, or blast crisis underwent marrow or blood stem cell transplantation from an HLA-matched sibling using high-dose thiotepa, busulfan and cyclophosphamide (TBC) as the preparative regimen. All evaluable patients engrafted and had complete donor chimerism. One patient failed to clear meningeal leukemia, and one patient had one of 30 metaphases positive for the Philadelphia chromosome at 2 months post transplant. The remainder of the patients studied had eradication of CML documented by cytogenetics and/or Southern blot for BCR gene rearrangement, and 13 of 15 patients studied became negative for the BCR gene rearrangement by polymerase chain reaction. Three-year relapse rate is 42% (95% CI, 19-64%). The relapse rate was significantly lower for patients transplanted without blast crisis (9% vs 100%, P Ͻ 0.001). Eight (22%, 95% CI, 10-39%) patients had severe or fatal veno-occlusive disease (VOD). Elevated liver enzymes within 1 month prior to transplantation and transplantation using marrow were significantly associated with the occurrence of VOD. Three-year survival is 28% (95% CI, 13-43%). Survival was significantly higher for patients transplanted without blast crisis (45% vs 0%, P = 0.01). TBC is an effective preparative regimen for CML in accelerated phase but not refractory blast crisis, and it should be used with caution in patients with prior hepatopathy who have an increased risk of severe VOD.
blast crisis and 15-40% for transplantation in accelerated or second chronic phase. [1] [2] [3] [4] [5] [6] [7] Busulfan-based preparative regimens have been favored by some for CML as a result of the potent anti-myeloid activity and ease of administration of busulfan, and results with the busulfan-cyclophosphamide regimen are similar to those achieved with cyclophosphamide and total body irradiation for patients with advanced CML. 8 
N,NЈ,NЈ-triethylenethiophosphoramide
(thiotepa) is a highly myelosuppressive alkylating agent that lacks overlapping toxicities with busulfan or cyclophosphamide. 9 We evaluated the combination of thiotepa with busulfan and cyclophosphamide as a preparative regimen to determine if addition of a third alkylating agent would improve outcome without increased toxicity. The maximal tolerated dose of this combination was previously identified in a phase I study. 10 Here we report the results using this novel regimen for transplantation of patients with advanced CML from HLA-identical donors.
Materials and methods

Eligibility criteria
From May 1991 to January 1996, patients with CML past first chronic phase having a t(9;22) documented by cytogenetics or Southern blot for rearrangement of the BCR gene were eligible for treatment on consecutive phase I-II studies of thiotepa, busulfan and cyclophosphamide as preparative regimen. Other requirements included age 15-55 years, Zubrod performance status 0-2, adequate organ function, and an HLA-matched related donor. 10, 11 Protocols were approved by the institutional review board of the MD Anderson Cancer Center, and written informed consent was obtained from all patients and donors.
Treatment
The preparative regimen consisted of thiotepa 150-250 mg/m 2 /day i.v. on days Ϫ9, Ϫ8 and Ϫ7, busulfan 1 mg/kg orally every 6 h on days Ϫ6, Ϫ5 and Ϫ4 (for a total of 12 doses), and cyclophosphamide 60 mg/kg/day i.v. on days Ϫ3 and Ϫ2 (TBC) with precautions and dose adjustments as described previously. 10, 11 Marrow or blood stem cells were collected as reported, 10, 11 and T cell depletion was not used. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus (FK506) or cyclosporine (CsA) with methylprednisolone, methotrexate, or immunotoxin. 10, 11 Standard post-transplant care was provided. Thirty-four patients received filgrastim post transplant to accelerate neutrophil recovery.
Monitoring post transplant
Patients were reviewed by one of the study collaborators at least weekly to day 100 and less frequently thereafter. Regimen-related toxicity was scored using the system of Bearman et al 12 except that death occurring after day 28 due to regimen-related toxicity was still considered grade 4. Monitoring for idiopathic interstitial pneumonitis, hemorrhagic cystitis and VOD continued to day 100. GVHD was graded according to the consensus criteria. 13 Marrow biopsies and aspirates were examined at 1, 3, 6, 12, 18 and 24 months after transplantation and annually thereafter. Hematopoietic chimerism was evaluated by restriction fragment length polymorphisms (RFLP). Residual disease was evaluated by conventional cytogenetics, Southern blot hybridization for a BCR gene rearrangement, and, in some cases, by polymerase chain reaction (PCR) for the bcr-abl transcript. 14 
Definitions
The criteria for blast crisis were у30% blasts in the marrow or blood, or any extramedullary collections of blasts, and the criteria for accelerated phase included у10% blasts in marrow or blood; Ն20% basophils and eosinophils in marrow or blood; cytopenia unrelated to therapy; and leukocytosis, thrombocytosis, adenopathy, splenomegaly or bone pain unresponsive to therapy. Patients with cytogenetic clonal evolution and no clinical evidence of accelerated phase were not eligible for these protocols. Neutrophil recovery was defined as the first of 3 consecutive days that the absolute neutrophil count exceeded the target value, and platelet recovery was defined as the day that the platelet count exceeded the target value with no platelet transfusions the following week. After transplantation, observation of the Philadelphia chromosome in two or more consecutive studies without abnormalities in the blood counts was considered a cytogenetic relapse. A white blood cell count greater than 10 × 10 9 /l with cytogenetic or molecular evidence of the Philadelphia chromosome but less than 5% blasts and no extramedullary disease was considered a hematologic relapse in chronic phase. High-risk cytogenetics include variant Ph, double Ph, +8, and 3p abnormalities. 15 
Statistical analyses
At time of analysis, median time from transplantation for all patients was 4.8 years (range, 2.4-7.1 years). Minimum follow-up for survivors was 3 years. Categorical data were compared using the Fisher exact test. The actuarial risks of GVHD, relapse, survival and treatment-related mortality were estimated according to Kaplan and Meier, and the logrank test was used to make comparisons. Confidence intervals for proportions were based on the binomial distribution.
Results
Patient characteristics
Thirty-six adults were transplanted (Table 1) . Twenty had clinical signs of accelerated disease, two were in у2nd chronic phase, five were in lymphoid blast crisis, and nine were in myeloid blast crisis. Thirteen of 15 patients treated with induction chemotherapy were refractory, and two had relapsed after allogeneic transplantation using a TBI-based preparative regimen.
Engraftment and GVHD
All patients who survived at least 28 days engrafted. The neutrophil count exceeded 0.5 × 10 Patient-donor pair sex-mismatched 11
Patient-donor pair CMV-seronegative 0 ently at 3 months post transplant and remains in remission 40 months post transplant, and two patients had mixed chimerism within 3 months prior to hematologic relapse. Grades 2-4 GVHD occurred in 49% (95%CI, 31-67%), and grades 3-4 GVHD in 21% (95% CI, 7-35%). Seventyfive percent of the patients survived at least 100 days, and the incidence of chronic GVHD in these patients was 83% (95% CI, 63-100%).
Regimen-related toxicity
The most common regimen-related complications were mucositis and elevated liver enzymes ( Table 2 ). Four patients (11%) had a grade 3 or 4 regimen-related toxicity, and two patients (6%) had a cumulative toxicity score у7.
Within the first 100 days post transplant, no patient developed idiopathic interstitial pneumonitis, and 28% had hemorrhagic cystitis. Twenty-two percent (95% CI, 10-39%) of the patients had severe VOD (total bilirubin Ն6 mg/dl), and two patients had fatal VOD. Severe VOD correlated with type of transplant (8/22 marrow recipients vs 0/14 blood stem cell recipients, P = 0.01), transaminases more than twice the upper level of normal within 1 month pre-transplant (7/12 with transaminitis vs 1/24 with normal liver enzymes, P = 0.006), and use of MTX for GVHD prophylaxis (5/10 using MTX vs 3/26 using MP, P = 0.02), but the risk of severe VOD was not related to phase of disease, positive hepatitis serology pre-transplant, and prior busulfan use or prior transplantation.
Residual disease and relapse
All evaluable patients had Ͼ5% blasts in the marrow when assessed 1 month post transplant, but one patient had persistent leptomeningeal leukemia. Within the first 3 months after transplantation, the BCR gene was germline in marrow samples from all 22 patients evaluated, and cytogenetics showed eradication of the Ph chromosome in 28 of 29 (97%) evaluated. The two patients with mixed chimerism by RFLP analysis 3 months prior to hematologic relapse had a germline BCR gene and normal cytogenetics at that timepoint. Thirteen (87%) of 15 patients studied achieved eradication of residual disease by PCR for bcr-abl transcripts; 11 of 14 (79%) were negative within 1 year post transplant, and one of five (20%) was positive more than 1 year post transplant. The actuarial relapse rate is (Table 3) .
Survival
Three-year survival is 28% (95% CI, 13-43%). Survival correlated with phase of disease at transplantation (Figure 1) but not with type of transplant, age or cytogenetic risk group (Table 3) . Median survival was 7 months for patients transplanted in blast crisis. Nine patients died in relapse, eight with GVHD, seven with infection, and two with regimen-related toxicity. Two-year treatment-related mortality is 48% (95% CI, 31-65%) and did not differ significantly by phase of disease.
Discussion
Although the combination of busulfan and cyclophosphamide has gained favor as a preparative regimen for allogeneic transplantation, it has limited efficacy for patients with advanced CML. 5, 6, 8, 16 In this study, we reduced the dose of busulfan to minimize toxicity and added a third alkylating agent, thiotepa, with the goal of improving efficacy. All patients achieved a medullary remission with TBC, and only one patient, treated at the lowest thiotepa dose level, failed to clear Ph-positive metaphases within the first 100 days post transplant. Furthermore, 79% of the patients studied were PCR-negative within 1 year post transplant, which appears superior to the 32% rate reported by Miyamura et al 17 in a meta-analysis of all published series of patients with CML transplanted past first chronic phase. These results demonstrate that even with the reduced dose of busulfan, TBC is effective for early control of disease.
For patients with CML in blast crisis, a second chronic phase can be achieved in 16-49% using combination chemotherapy, with a higher response rate reported for patients with lymphoid blast morphology. 18, 19 Median survival is approximately 6 months for all blast crisis patients and less than 3 months for those refractory to standard-dose induction therapy. Median survival post transplant for our patients in blast crisis, 7 months, was somewhat longer than with standard-dose induction therapy, despite the fact that almost all were refractory to induction chemotherapy, but the relapse rate was high for this group, and there are no long-term survivors. It is clear that TBC is not an active regimen for patients with CML in refractory blast crisis. In this regard, it has no apparent advantage over standard preparative regimens which are associated with a 0-25% survival. 1, 2, 4, 7 However, the efficacy of TBC for untreated blast crisis is unknown.
By contrast, only one of our patients with CML in accelerated or second chronic phase has relapsed, and the longterm survival, 45%, is somewhat better than that reported historically for this subgroup of patients. [1] [2] [3] 7 The improved disease control may reflect the addition of thiotepa to the preparative regimen; however, potential differences in patient characteristics preclude a truly meaningful comparison of outcomes in different reports. The toxicity profile of the TBC regimen has been evaluated and is largely similar to that of the standard combinations of busulfan and cyclophosphamide or cyclophosphamide and total body irradiation. 20 The experience with the current population is noteworthy for the relatively high incidence of severe VOD (22%). A number of treatmentrelated and patient-related factors have been identified as predisposing patients to development of VOD after allogeneic transplantation. [21] [22] [23] Elevated liver enzymes pre-transplant is the most common prognostic factor for VOD in all series and was the most significant predictor of severe VOD in our patients. Thus, the TBC regimen may not be suitable for CML patients with impaired hepatic function following extensive treatment with conventional chemotherapy or with a prior history of hepatitis as defined by an elevation of serum transaminases. More recently, the unpredictable absorption and interpatient variability in disposition of oral busulfan has been appreciated, 24, 25 and a correlation between busulfan levels and VOD has been reported by some. 26 The recent availability of an intravenous form of busulfan 27 will allow better control of busulfan levels and may reduce the hepatic complications in patients treated with TBC.
